The Use of Wearable ECG Monitors in Detecting Cardiac Risks Associated with Diabetes

Diabetes mellitus affects more than 500 million adults worldwide, and the number continues to rise. Among the most feared complications of diabetes is cardiovascular disease, which remains the leading cause of morbidity and mortality in this population. The relationship between diabetes and cardiac risk is complex and bidirectional—uncontrolled blood glucose accelerates atherosclerosis, while cardiac autonomic neuropathy and silent ischemia make detection difficult. Traditional diagnostic methods, such as in-clinic electrocardiograms (ECGs), capture only a brief snapshot of cardiac activity, often missing transient arrhythmias or ischemic episodes. Wearable ECG monitors have emerged as a transformative tool that bridges this gap, providing continuous, real-time cardiac surveillance in daily life. This article explores how wearable ECG monitors are improving the early detection of cardiac risks in diabetic patients, the underlying mechanisms, current evidence, benefits, challenges, and future directions.

Understanding Wearable ECG Monitors

How They Work

Wearable ECG monitors are portable devices that record the heart's electrical activity over extended periods, ranging from hours to weeks. Unlike a standard 12-lead ECG performed in a clinic or hospital, wearable devices use a smaller number of electrodes—often two to six—embedded in patches, wristbands, chest straps, or even rings. The electrodes detect the voltage changes produced by each heartbeat and transmit the data via Bluetooth or near-field communication to a paired smartphone, tablet, or cloud platform. Advanced algorithms then analyze the rhythm for abnormalities such as atrial fibrillation (AFib), bradycardia, tachycardia, or premature ventricular contractions.

Types of Wearable ECG Devices

  • Patch monitors: Single-use, adhesive patches worn on the chest for up to 14 days. Examples include the Zio Patch (iRhythm) and Carnation Ambulatory Monitor (Bardy Diagnostics). These are prescription-only and medical-grade.
  • Smartwatches: Consumer devices like the Apple Watch (Series 4 and later), Samsung Galaxy Watch, and Fitbit Sense incorporate single-lead ECG capabilities. They allow on-demand recordings and passive monitoring for irregular rhythms.
  • Handheld units: Devices such as the KardiaMobile (AliveCor) require the user to place fingers on two electrodes for a 30-second recording. They are pocket-sized and integrated with smartphone apps.
  • Continuous monitoring patches with event detection: Some newer patches use artificial intelligence to store only abnormal strips, reducing data volume while ensuring critical events are captured.

Diabetes and Cardiac Risks: The Silent Epidemic

Patients with diabetes face two to four times higher risk of developing heart disease compared to those without diabetes. This elevated risk arises from multiple mechanisms:

  • Accelerated atherosclerosis: Chronic hyperglycemia damages the endothelium and promotes plaque formation in coronary arteries.
  • Cardiac autonomic neuropathy (CAN): Nerve damage affecting the heart’s regulatory system leads to resting tachycardia, exercise intolerance, and blunted response to ischemia. CAN can mask the typical chest pain of a heart attack, a phenomenon known as silent ischemia.
  • Diabetic cardiomyopathy: A distinct condition causing diastolic dysfunction and heart failure even in the absence of coronary artery disease.
  • Electrolyte imbalances: Fluctuations in potassium and magnesium due to nephropathy or insulin therapy can trigger dangerous arrhythmias.

The problem is that many of these conditions are asymptomatic in their early stages. A standard 12-lead ECG performed annually may not detect intermittent arrhythmias or transient ischemic changes. Wearable ECG monitors address this gap by providing longitudinal data that can reveal patterns invisible to spot-checks.

How Wearable ECG Monitors Help Diabetic Patients

Early Detection of Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that increases stroke risk by fivefold. Diabetes is an independent risk factor for AFib, and individuals with both conditions have worse outcomes. Wearable ECG monitors can detect AFib episodes, including asymptomatic or paroxysmal episodes that are often missed in clinic. Studies have shown that consumer smartwatches can identify AFib with high sensitivity and specificity in real-world populations. For example, the Apple Heart Study (2019) enrolled over 419,000 participants and found that the watch’s irregular rhythm notification algorithm had a positive predictive value of 71% for AFib. While not a substitute for clinical diagnosis, these devices empower patients to seek timely evaluation.

Monitoring Heart Rate Variability

Heart rate variability (HRV) is the beat-to-beat variation in heart rate and is a marker of autonomic nervous system function. Reduced HRV is a hallmark of CAN and a strong predictor of cardiovascular mortality in diabetes. Wearable ECG monitors can compute HRV metrics from continuous recordings, allowing clinicians to detect early autonomic dysfunction before symptoms occur. Some devices provide daily HRV trends that patients can share with their care team, enabling proactive interventions such as tight glycemic control or pharmacologic therapy.

Identifying Silent Ischemia

Silent myocardial ischemia—oxygen deprivation without chest pain—is particularly common in diabetes due to autonomic neuropathy. Wearable devices with ST-segment monitoring capabilities (mostly medical-grade patches) can detect ischemic events during daily activities or during sleep. Although consumer smartwatches currently lack reliable ST-segment analysis, research is underway to develop algorithms that use lead‑depleted ECGs for ischemia detection. In the interim, clinical patches remain the gold standard for ambulatory ischemia monitoring in high-risk diabetic patients.

Post-Operative and Periprocedural Risk Reduction

Diabetic patients undergoing surgery (e.g., coronary bypass, valve repair) or interventional procedures (e.g., pacemaker implantation) benefit from wearable ECG monitoring post-discharge. These devices can flag arrhythmias caused by electrolyte shifts, catecholamine surges, or mechanical changes, reducing readmission rates. Hospitals increasingly use patch monitors for 30-day remote telemetry after cardiac surgery in diabetic cohorts.

Benefits for Patients and Healthcare Systems

  • Improved patient engagement: Wearables provide real-time feedback, motivating patients to adhere to diet, exercise, and medication regimens. Seeing a “normal” rhythm after lifestyle changes reinforces positive behaviors.
  • Remote monitoring and telemedicine: Data from wearable ECG monitors can be integrated into electronic health records (EHRs) and reviewed by cardiologists remotely. This reduces the need for in-person visits, particularly valuable in rural or underserved areas.
  • Cost-effectiveness: While the upfront cost of a prescription patch may be several hundred dollars, it often prevents expensive emergency department visits or hospitalizations for undiagnosed arrhythmias. Cost-effectiveness analyses show that screening for AFib using wearables in patients with diabetes is favorable compared to no screening.
  • Personalized care: Continuous data allows clinicians to titrate antiarrhythmic medications, anticoagulants, or beta-blockers based on real-world rhythm patterns rather than intermittent snapshots.
  • Early warning for hypoglycemia: Emerging research indicates that certain ECG changes (e.g., prolonged QT interval) precede hypoglycemic episodes. Wearable monitors could serve as an early alert system, especially for patients with hypoglycemia unawareness.

Challenges and Limitations

Accuracy and False Positives

Although wearable ECG monitors have improved, they are not infallible. Motion artifacts, poor skin contact, and interference from muscle tremors can generate false alarms. In diabetic patients, peripheral neuropathy or tremors may degrade signal quality. A false positive for AFib can cause unnecessary anxiety, additional medical visits, and even inappropriate anticoagulation. Algorithms continue to evolve, but clinicians must interpret wearable data with caution and confirm findings with a standard 12-lead ECG or longer-term monitoring when necessary.

Data Privacy and Security

Wearable devices generate sensitive health data that, if breached, could be used for discrimination or insurance adjustments. Patients must be educated about the data-sharing policies of device manufacturers and healthcare systems. Regulatory frameworks such as HIPAA in the United States and GDPR in Europe govern how this data can be stored and transmitted, but enforcement across consumer-grade devices can be inconsistent.

Reimbursement and Access

While some medical-grade patches are covered by insurance for specific indications (e.g., suspected arrhythmia), many consumer devices are not reimbursed. Out-of-pocket costs can be a barrier for lower-income diabetic patients, who are already at higher risk for poor outcomes. Disparities in access may widen the health equity gap. Expanding reimbursement for remote cardiac monitoring in diabetes is an important policy goal.

Patient Adherence

Wearing a patch for 7–14 days requires skin tolerance and behavioral compliance. Skin irritation, sweating, and discomfort can lead to early removal. Smartwatches, while less obtrusive, require regular charging and willingness to wear continuously. Studies report variable adherence rates, with 75–90% of patients completing the prescribed monitoring period. Educational support and device selection tailored to patient preferences can improve adherence.

Interpretation Burden

Continuous monitoring generates enormous amounts of data. Without efficient triage tools, the burden on healthcare providers can become unsustainable. AI-based algorithms help filter noise, but false positives still require human review. Healthcare systems must invest in staffing and workflow redesign to manage the data load effectively.

Current Evidence and Real-World Outcomes

Several large trials have investigated the use of wearable ECG monitors in populations with or at risk for diabetes. The mSToPS trial (2018) randomized elderly patients, many with diabetes, to immediate monitoring with a patch vs. usual care. Those who received the patch had a higher rate of AFib detection (6.3%) compared to usual care (0.9%), and the monitoring group had lower rates of stroke and hospitalization at one-year follow-up. The REHEARSE-AF study used AliveCor devices in community settings to detect AFib in patients with hypertension and diabetes, demonstrating a 10-fold increase in diagnosis compared to routine care. More recently, the Apple Heart Study and Fitbit Heart Study have provided real-world evidence that consumer wearables can effectively identify asymptomatic arrhythmias in large, diverse populations. However, these studies enrolled volunteers, and the generalizability to all diabetic patients, including those with cognitive or financial limitations, requires further investigation.

In a subset analysis of the mSToPS trial focusing on participants with diabetes, the detection rate of AFib was even higher, and the benefit of monitoring was more pronounced. Another study using the KardiaMobile device in diabetic patients with palpitations found that 12% had actionable arrhythmias not captured on standard ECG. Real-world data from clinical practices also show that patients with diabetes who use wearable monitors have higher rates of anticoagulation initiation for newly diagnosed AFib, potentially reducing stroke risk.

Future Directions

Integration with Continuous Glucose Monitors

The next frontier is combining wearable ECG data with continuous glucose monitoring (CGM). Hypoglycemia and hyperglycemia both induce cardiac electrophysiological changes (e.g., prolonged QT interval, ST-segment depression). Closed-loop systems that leverage both heart rate and glucose data could alert patients to impending dangerous events before they become symptomatic. Early research on devices like the Dexcom G7 paired with an Apple Watch shows that such integration is technically feasible and may improve hypoglycemia detection by correlating ECG changes with glucose trends.

Artificial Intelligence–Enhanced Diagnostics

Machine learning models trained on large ECG databases can now detect subtle patterns indicating future arrhythmia risk, such as low QRS voltage or T‑wave alternans. In diabetic patients, AI algorithms are being developed to predict cardiac autonomic neuropathy from raw ECG data, potentially replacing costly autonomic reflex tests. Companies like iRhythm and CardioDiagnostics are deploying cloud‑based AI to provide near‑instantaneous rhythm interpretation, reducing the burden on human readers.

Implantable Wearables and Long‑Term Monitoring

Micro‑electrode patches that can be worn for months without replacement are under development. These devices would allow continuous monitoring for years, capturing rare arrhythmias that occur only a few times per year. For diabetic patients with a high risk of sudden cardiac death, such long‑term recording could substantially improve event detection and allow earlier intervention with implantable cardioverter‑defibrillators.

Wearable ECG in Clinical Decision Support

As wearable data becomes more integrated with EHR systems, clinical decision support tools can automatically flag patients with concerning trends. For example, a dashboard that shows declining HRV over weeks in a diabetic patient could prompt an autonomic reflex test or a referral to a cardiologist. Such systems are already being piloted in large health systems and show promise in reducing the time to diagnosis of CAN.

Practical Recommendations for Healthcare Providers

  • Screen diabetic patients for cardiac risk factors and consider a baseline 12‑lead ECG followed by an extended Holter or patch monitor if they have any symptoms (palpitations, dizziness, syncope) or high‑risk features (long diabetes duration, autonomic symptoms, known vascular disease).
  • Discuss the role of consumer wearables with motivated patients who are interested in tracking their own health. Provide guidance on device selection, proper use, and when to share data with the care team.
  • Integrate wearable data into clinical workflows by establishing protocols for reviewing remote monitoring reports, handling alerts, and responding to patient inquiries. Avoid alert fatigue by defining thresholds that trigger physician notification.
  • Educate patients on limitations—wearable ECGs are screening tools, not diagnostic devices. Emphasize that any abnormal reading requires follow‑up with a healthcare professional.
  • Consider cost and insurance coverage when recommending specific devices. For patients without insurance coverage for patches, a smartwatch with ECG capability may be a more affordable option despite lower diagnostic accuracy.

Conclusion

Wearable ECG monitors represent a powerful evolution in the management of cardiac risk associated with diabetes. By providing continuous, real‑world data, these devices help detect silent arrhythmias, autonomic dysfunction, and ischemic episodes that would otherwise go unnoticed. While challenges related to accuracy, access, and data privacy remain, the trajectory of innovation is promising. As technology becomes more integrated into diabetes care, wearable ECG monitoring will likely become a standard component of comprehensive cardiovascular risk reduction. For clinicians, the message is clear: staying informed about these tools and incorporating them appropriately into patient care can lead to earlier diagnosis, better outcomes, and ultimately, saved lives.

Resources and Further Reading